AR050733A1 - Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios - Google Patents
Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatoriosInfo
- Publication number
- AR050733A1 AR050733A1 ARP050103762A ARP050103762A AR050733A1 AR 050733 A1 AR050733 A1 AR 050733A1 AR P050103762 A ARP050103762 A AR P050103762A AR P050103762 A ARP050103762 A AR P050103762A AR 050733 A1 AR050733 A1 AR 050733A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- groups
- alkyl
- atoms
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Abstract
La presente trata de derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios. Reivindicacion 1: Estereoisomeros de la formula general (1), caracterizados porque R1 y R2 son, independientemente entre sí, un átomo de H, un grupo hidroxi, un átomo de halogeno, un grupo alquilo C1-10 opcionalmente sustituido, un grupo alcoxi C1-10, un grupo alquiltio C1-10, un grupo perfluoralquilo C1-5, un grupo ciano, un grupo nitro o R1 y R2 son, juntos, un grupo seleccionado de entre los grupos -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH-, -(CH2)n+2, -NH-(CH2)n+1, N(C1-3-alquilo)-(CH2)n+1, -NH-N=CH-, donde n = 1 o 2 y los átomos en posicion final están unidos con átomos de C del anillo directamente adyacentes, o NR9R10, donde R9 y R10 pueden ser, independientemente entre sí, H, alquil C1-5 o (CO)-alquil C1-5; R3 es un átomo de H, un grupo hidroxi, un átomo de halogeno, un grupo alquilo C1-10 opcionalmente sustituido, un grupo alcoxi C1-10, un grupo alquiltio C1-10, un grupo perfluoralquilo C1-5, un grupo ciano; R4 es un grupo alquilo C1-10, un grupo alquilo C1-10 sustituido por uno o varios grupos seleccionados de grupos hidroxi, átomos de halogeno, grupos alcoxi C1-5; un grupo cicloalquilo C3-7 opcionalmente sustituido, un grupo heterociclilo que puede ser sustituido, un grupo arilo que puede ser sustituido, un grupo heteroarilo mono- o bicíclico opcionalmente sustituido por uno o varios grupos seleccionados de grupos alquilo C1-5 (que opcionalmente puede ser sustituido por 1-3 grupos hidroxi o 1-3 grupos COOR6), grupos alcoxi C1-5, grupos hidroxi, átomos de halogeno, grupos exoalquilideno C1-3 que contiene opcionalmente 1-4 átomos de N y/o 1-2 átomos de O y/o 1- 2 átomos de S y/o 1-2 grupos ceto, donde este grupo puede estar unido con la amina del sistema tetrahidronaftaleno en cualquier posicion y puede estar hidrogenado en uno o varios lugares y R12 es un grupo alquilo C1-5 o un grupo bencilo; R5 es un grupo hidroxi, un grupo OR11 o un grupo O-(CO)R11, donde R11 es cualquier grupo protector hidroxi o un grupo alquilo C1-10; R6 es un grupo alquilo C1-5 o un grupo alquilo C1-5 que puede ser total o parcialmente fluorado, un grupo cicloalquilo C3-7, un grupo cicloalquilo C3-7-alquilo C1-8, cicloalquilo C3-7-alquenilo C2-8, un grupo heterociclilo, un grupo heterociclilo-alquilo C1-8, un grupo heterociclilo-alquenilo C2-8, un grupo arilo, un grupo arilo-alquilo C1-8, arilo-alquenilo C2-8, arilo- alquinilo C2-8, un grupo heteroarilo mono- o bicíclico opcionalmente sustituido por uno o varios grupos ceto, grupos alquilo C1-5, grupos alcoxi C1-5, átomos de halogeno, grupos exoalquilideno C1-3 que contienen uno o varios átomos de N y/o átomos de O y/o átomos de S, un grupo heteroarilo-alquilo C1-8 o un grupo heteroarilo-alquenilo C2-8, donde estos grupos pueden estar unidos en cualquier posicion con el sistema tetrahidronaftaleno y pueden ser hidrogenados en uno o varios lugares; R7y R8 son independientemente entre sí, un átomo e H, un átomo de halogeno, un grupo alquilo C1-5, que puede estar sustituida con OR10, SR10, N(R1R10), o junto con el átomo de C del grupo metileno son un anillo cicloalquilo C3-6, o R1 y R8 juntos son un carbo-o heterociclo condensado de 5 a 8 miembros, saturado o insaturado, que opcionalmente está sustituido por 1-2 grupos ceto, 1-2 grupos alquilo C1-5, 1-2 grupos alcoxi C1-5, 1-2 grupos hidroxi, 1-4 átomos de halogeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004044680A DE102004044680B3 (de) | 2004-09-09 | 2004-09-09 | Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050733A1 true AR050733A1 (es) | 2006-11-15 |
Family
ID=35517445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103762A AR050733A1 (es) | 2004-09-09 | 2005-09-09 | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1786823B1 (es) |
| JP (1) | JP2008512416A (es) |
| KR (1) | KR20070050469A (es) |
| CN (1) | CN101065386A (es) |
| AR (1) | AR050733A1 (es) |
| AT (1) | ATE384069T1 (es) |
| AU (1) | AU2005281859A1 (es) |
| BR (1) | BRPI0515186A (es) |
| CA (1) | CA2577861A1 (es) |
| DE (2) | DE102004044680B3 (es) |
| EA (1) | EA200700550A1 (es) |
| EC (1) | ECSP077306A (es) |
| ES (1) | ES2301056T3 (es) |
| GT (1) | GT200500241A (es) |
| IL (1) | IL181832A0 (es) |
| MX (1) | MX2007002833A (es) |
| NO (1) | NO20071805L (es) |
| PA (1) | PA8644701A1 (es) |
| PE (1) | PE20060596A1 (es) |
| RS (1) | RS20070095A (es) |
| SV (1) | SV2006002220A (es) |
| TW (1) | TW200621703A (es) |
| UY (1) | UY29109A1 (es) |
| WO (1) | WO2006027236A1 (es) |
| ZA (1) | ZA200701399B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| JP4638438B2 (ja) | 2003-10-08 | 2011-02-23 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | テトラヒドロナフタレン誘導体類、それらの生成方法及び抗−炎症剤としてのそれらの使用 |
| US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| DE102004063227A1 (de) * | 2004-12-22 | 2006-07-06 | Schering Ag | Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| EP1834948A1 (de) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| EP1917963A1 (en) * | 2006-10-31 | 2008-05-07 | Bayer Schering Pharma Aktiengesellschaft | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents |
| AU2008219115A1 (en) | 2007-02-16 | 2008-08-28 | Synta Pharmaceuticals Corp. | Substituted fused-ring compounds for inflammation and immune-related uses |
| EP2072509A1 (en) | 2007-12-18 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0800517A1 (en) * | 1994-12-29 | 1997-10-15 | Allergan | Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
| DE10038639A1 (de) * | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| PT1490062E (pt) * | 2002-03-26 | 2008-01-30 | Boehringer Ingelheim Pharma | Miméticos de glucocorticóides, métodos para a sua preparação, composições farmacêuticas e suas utilizações |
| DE10215316C1 (de) * | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| JP4638438B2 (ja) * | 2003-10-08 | 2011-02-23 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | テトラヒドロナフタレン誘導体類、それらの生成方法及び抗−炎症剤としてのそれらの使用 |
-
2004
- 2004-09-09 DE DE102004044680A patent/DE102004044680B3/de not_active Expired - Fee Related
-
2005
- 2005-09-02 CN CNA2005800383722A patent/CN101065386A/zh active Pending
- 2005-09-02 GT GT200500241A patent/GT200500241A/es unknown
- 2005-09-02 RS RSP-2007/0095A patent/RS20070095A/sr unknown
- 2005-09-02 EA EA200700550A patent/EA200700550A1/ru unknown
- 2005-09-02 AU AU2005281859A patent/AU2005281859A1/en not_active Abandoned
- 2005-09-02 ES ES05786302T patent/ES2301056T3/es active Active
- 2005-09-02 WO PCT/EP2005/009623 patent/WO2006027236A1/de active IP Right Grant
- 2005-09-02 JP JP2007530646A patent/JP2008512416A/ja not_active Withdrawn
- 2005-09-02 EP EP05786302A patent/EP1786823B1/de active Active
- 2005-09-02 BR BRPI0515186-4A patent/BRPI0515186A/pt not_active Application Discontinuation
- 2005-09-02 MX MX2007002833A patent/MX2007002833A/es not_active Application Discontinuation
- 2005-09-02 KR KR1020077005549A patent/KR20070050469A/ko not_active Application Discontinuation
- 2005-09-02 DE DE502005002595T patent/DE502005002595D1/de not_active Expired - Fee Related
- 2005-09-02 AT AT05786302T patent/ATE384069T1/de not_active IP Right Cessation
- 2005-09-02 CA CA002577861A patent/CA2577861A1/en not_active Abandoned
- 2005-09-06 TW TW094130577A patent/TW200621703A/zh unknown
- 2005-09-08 PA PA20058644701A patent/PA8644701A1/es unknown
- 2005-09-08 SV SV2005002220A patent/SV2006002220A/es not_active Application Discontinuation
- 2005-09-08 PE PE2005001041A patent/PE20060596A1/es not_active Application Discontinuation
- 2005-09-08 UY UY29109A patent/UY29109A1/es not_active Application Discontinuation
- 2005-09-09 AR ARP050103762A patent/AR050733A1/es unknown
-
2007
- 2007-02-16 ZA ZA200701399A patent/ZA200701399B/xx unknown
- 2007-03-08 EC EC2007007306A patent/ECSP077306A/es unknown
- 2007-03-08 IL IL181832A patent/IL181832A0/en unknown
- 2007-04-03 NO NO20071805A patent/NO20071805L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL181832A0 (en) | 2007-07-04 |
| GT200500241A (es) | 2006-08-17 |
| ATE384069T1 (de) | 2008-02-15 |
| NO20071805L (no) | 2007-06-07 |
| EA200700550A1 (ru) | 2007-10-26 |
| ECSP077306A (es) | 2007-04-26 |
| EP1786823A1 (de) | 2007-05-23 |
| CN101065386A (zh) | 2007-10-31 |
| SV2006002220A (es) | 2006-03-15 |
| ZA200701399B (en) | 2008-09-25 |
| RS20070095A (en) | 2008-11-28 |
| ES2301056T3 (es) | 2008-06-16 |
| PA8644701A1 (es) | 2006-07-03 |
| DE502005002595D1 (de) | 2008-03-06 |
| DE102004044680B3 (de) | 2006-06-08 |
| BRPI0515186A (pt) | 2008-07-22 |
| CA2577861A1 (en) | 2006-03-16 |
| KR20070050469A (ko) | 2007-05-15 |
| AU2005281859A1 (en) | 2006-03-16 |
| EP1786823B1 (de) | 2008-01-16 |
| TW200621703A (en) | 2006-07-01 |
| PE20060596A1 (es) | 2006-07-26 |
| UY29109A1 (es) | 2006-03-31 |
| WO2006027236A1 (de) | 2006-03-16 |
| JP2008512416A (ja) | 2008-04-24 |
| MX2007002833A (es) | 2007-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050733A1 (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios | |
| AR046062A1 (es) | Derivados de tetrahidronaftaleno procedimiento para su preparacion y su uso antiinflamatorio | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| PE20220140A1 (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR059896A1 (es) | Derivados estereoisomericos de tetrahidronaftaleno, metodo de preparacion, medicamentos que los contienen, y uso como agentes antiinflamatorios. | |
| AR030324A1 (es) | Derivados de 4-fenil-piridina | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR051248A1 (es) | Derivados de 3-arilamino piridina | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| AR076707A1 (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| AR055016A1 (es) | Aminoalcoholes triciclicos, procedimientos para su preparacion y su uso para la preparacion de medicamentos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| AR056949A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion | |
| AR029717A1 (es) | Derivados del pro-farmaco de 4-fenil-piridina | |
| AR049965A1 (es) | Moduladores de androgenos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |